Johnson & Johnson: Diabetes Mellitus, Type 2 trials

The registry lists 56 Diabetes Mellitus, Type 2 studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 22 have results posted.

Phase 1 16Phase 2 9Phase 3 16Phase 4 4No phase 11(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes MellitusCompletedNCT03586830Phase 2Results posted
• An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on MetforminCompletedNCT03267576Phase 4Results posted
• A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes MellitusCompletedNCT03170518Phase 3Results posted
• Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic NephropathyCompletedNCT02065791Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and SitagliptinCompletedNCT02025907Phase 4Results posted
• A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes MellitusCompletedNCT01989754Phase 4Results posted
• Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive AgentsCompletedNCT01939496Phase 4Results posted
• A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and ExerciseCompletedNCT01809327Phase 3Results posted
• A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a SulphonylureaCompletedNCT01381900Phase 3Results posted
• An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin MonotherapyCompletedNCT01340664Phase 2Results posted
• A Study of Multiple Oral Doses of JNJ-41443532 in Patients With Type 2 Diabetes MellitusCompletedNCT01230749Phase 2Results posted
• The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)CompletedNCT01137812Phase 3Results posted
• The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)CompletedNCT01106690Phase 3Results posted
• The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)CompletedNCT01106677Phase 3Results posted
• A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes MellitusCompletedNCT01106651Phase 3Results posted
• The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)CompletedNCT01106625Phase 3Results posted
• The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) TrialCompletedNCT01081834Phase 3Results posted
• An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal ImpairmentCompletedNCT01064414Phase 3Results posted
• CANVAS - CANagliflozin cardioVascular Assessment StudyCompletedNCT01032629Phase 3Results posted
• CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus GlimepirideCompletedNCT00968812Phase 3Results posted
• An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 DiabetesCompletedNCT00642278Phase 2Results posted
• Clinical Benefits of a Blood Glucose Monitoring System in Patients With Type 2 DiabetesCompletedNCT00401622Not applicableResults posted
• Evidence for Health Improvement in People With Diabetes Using One Touch & Partner SolutionsStatus unknownNCT05354297Not applicable
• A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical SettingCompletedNCT03604224
• A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular DiseaseCompletedNCT03492580
• Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)CompletedNCT03249506
• A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes MellitusCompletedNCT03235219Phase 1
• Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM)TerminatedNCT02862431Phase 1
• Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United StatesCompletedNCT02857764
• An Observational Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea in Type 2 Diabetes Patients During RamadanCompletedNCT02737657
• An Observational Study to Assess the Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in CanadaCompletedNCT02688075
• Study on Incidence of Diabetic Ketoacidosis Among Participants With Type 2 Diabetes Mellitus Treated With Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors or Other Antihyperglycemic AgentsCompletedNCT02636192
• Safety, Pharmacokinetics, and Pharmacodynamics Study of Single Dose of CNTO 3649 in Healthy Adult Men and Multiple Doses of CNTO 3649 in Participants With Type 2 Diabetes MellitusCompletedNCT02224118Phase 1
• Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)CompletedNCT02009488Phase 1
• A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes MellitusCompletedNCT02000700Phase 1
• A Study of the Effects of Canagliflozin on Plasma Volume in Patients With Type 2 Diabetes MellitusCompletedNCT01483781Phase 1
• A Study of the Safety and Pharmacokinetics of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients With Type 2 DiabetesCompletedNCT01427699Phase 2
• A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes MellitusCompletedNCT01381887Phase 1
• A Study of Two Methods for Determining the Renal Threshold for Glucose in Patients With Type 2 Diabetes MellitusCompletedNCT01273558Phase 1
• A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes MellitusCompletedNCT01177163Phase 1
• A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes MellitusCompletedNCT01128985Phase 1
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and SitagliptinCompletedNCT01054118Phase 1
• A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes MellitusCompletedNCT00963768Phase 1
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of JNJ-38431055 in Volunteers With Type 2 Diabetes MellitusTerminatedNCT00946972Phase 1
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-38431055 in Healthy Male VolunteersCompletedNCT00910923Phase 1
• A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes MellitusCompletedNCT00882726Phase 1
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (Explores What the Body Does to the Drug), and Pharmacodynamics (Explores What a Drug Does to the Body) of JNJ-38431055 in Volunteers With Type 2 Diabetes MellitusCompletedNCT00871507Phase 1
• Remote Monitoring in Diabetes Disease ManagementCompletedNCT00675311Not applicable
• A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 DiabetesCompletedNCT00672386Phase 2
• Mode of Action of Topiramate in the Treatment of Obese Patients With and Without Type 2 Diabetes MellitusCompletedNCT00304603
• A Study of the Safety and Effectiveness of Topiramate on Insulin Sensitivity in Overweight or Obese Patients With Type 2 DiabetesCompletedNCT00236626Phase 2
• A Study To Evaluate The Effect Of Topiramate On Clinical And Electrophysiological Parameters In Subjects With Diabetic Peripheral PolyneuropathyCompletedNCT00231673Phase 2
• A Study of the Efficacy and Safety of Topiramate in the Treatment fo Obese, Type 2 Diabetic Patients Treated With MetforminCompletedNCT00231660Phase 3
• A Study on Efficacy and Safety of Topiramate OROS Controlled-Release in Obese, Type 2 Diabetic Subjects Managed With Diet or MetforminCompletedNCT00231647Phase 2
• A Study of the Efficacy and Safety of Topiramate in Obese, Type 2 Diabetic Patients Inadequately Controlled on Sulfonylurea TherapyTerminatedNCT00231634Phase 3
• A Study of the Safety and Efficacy of Topiramate in the Treatment of Obese, Type 2 Diabetes Patients on a Controlled DietCompletedNCT00231530Phase 3